The City of London's vanishing analysts

Extel’s 2026 U.K. SMID broker rankings highlight continued pressure on equity research, with small- and mid-cap retail analysts down to 17 from 29 in 2007 and support services analysts falling to 20 from 26. Sector coverage has also shrunk from 18 sectors to 9, reflecting the lingering impact of MiFID II, though FCA rule changes allowing some unbundling of research payments may support a gradual recovery. The article argues that renewed demand for research and younger analyst talent will be key to reviving London market liquidity.

Analysis

The decline in U.K. broker research is not just a nostalgia story; it is a liquidity and price-discovery problem that disproportionately hits domestically focused small- and mid-cap names. Fewer analysts means wider bid/ask spreads, lower institutional coverage, and a higher cost of capital for companies that cannot rely on global passive ownership to maintain attention. That creates a self-reinforcing loop: weaker coverage reduces trading activity, which further degrades the economics of making a market in the space.

The marginal beneficiaries are the remaining scaled brokers and diversified franchises with enough distribution to monetize research as an adjacently sold service rather than a standalone profit center. DB has optionality here because large-bank balance sheets and cross-border client relationships let it absorb lower-margin UK equities while still capturing wallet share through execution, financing, and corporate access; boutique competitors remain structurally vulnerable if research payments only partially re-bundle and buy-side budgets stay tight. The second-order effect is that issuer-sponsored activity and private-capital channels will likely take share from traditional public-market research, especially for newer listings and neglected sectors.

The contrarian point is that this may be less a full-cycle recovery than a cyclical bounce from an artificially depressed base. If the buy side only re-bundles a subset of research spend, economics improve for the top 5-7 providers but not enough to rebuild the analyst bench meaningfully, so sector breadth may continue shrinking even if headline rankings stabilize. That keeps the long-duration risk tilted toward continued concentration in U.K. equity market access, not a broad revival.

Key Decisions for Investors

• Long DB / short a basket of UK small-cap brokers and research-dependent boutiques over 3-6 months: DB has diversified monetization and can absorb uneven research demand, while smaller names face persistent fee pressure and weaker operating leverage.
• Add a tactical long in UK-listed small-cap liquidity proxies after any selloff in the next 1-2 quarters; use tight stops because coverage shrinkage is a slow-burn negative, but any re-bundling can produce short squeezes in illiquid names.
• Avoid or underweight pure-play UK equity research/execution models for now; the risk/reward remains poor until analyst headcount and sector breadth expand for at least two reporting cycles.
• If seeking a contrarian catalyst trade, buy 6-12 month call spreads on the most scaled UK-market intermediary rather than outright equity; the upside comes from a modest re-rating on improved research economics, while downside is capped if the revival proves partial.